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LETTERS TO THE EDITOR
Residents with military obligation face discrimination
This is the time of year when surgical residents interested in a
career in vascular surgery interview for fellowship positions, and
vascular fellows about to finish their training, interview for practice
opportunities. Naturally, the interviewing program directors and
the department chairmen try to get the best residents or fellows.
Unfortunately, in this process, I have noticed that a subtle bias
has developed in some programs against candidates who have a
future military obligation. These candidates are recipients of mili-
tary stipends and are required to serve in the reserves after com-
pleting their training. It is very rare that they are called to serve a
tour of duty while they are in training. Should they be called, albeit
rarely, it can cause an inconvenience to the program. The incon-
venience and stress caused to the individual and his family is
manifold. I speak from personal experience, having served in
Kosovo, Afghanistan, and Iraq in the last 4 years while working as
a vascular surgeon in a civilian group practice.
Every program is aware that it cannot discriminate on the basis
of age and ethnicity and therefore asking about these is inappro-
priate and illegal. I would like to remind all the program directors
and department chairmen that discriminating on the basis of
military service or obligation is also illegal. In my opinion, it is also
unethical and unpatriotic. I hope that after reading this letter,
candidates will not be asked about their military affiliation, so that
there is not even an appearance of bias. I am sure that the commu-
nity of vascular surgeons, many of whom are veterans themselves,
want the best care for our injured men and women in the battle-
field.
Narayan Deshmukh, MD
Colonel (retired), US Army Reserve
Sayre, Penn
doi:10.1016/j.jvs.2005.04.002
Regarding “Compelling nature of arterial
manifestations in Behçet disease”
I read with great interest the report from Iscan et al.1 My
experience supports the authors’ conclusions concerning arterial
complications of Behçet disease. I would like to point out, how-
ever, that this disease should be reported as Adamantiades-Behçet
disease. This is because it was the Greek ophthalmologist Benedict
Adamantiades (1875-1962) who in contemporary times first orally
presented this disease at the Medical Society of Athens in 1930,
and a year later he published it. 2 Six years later, the Turkish
dermatologist Hulusi Behçet (1889-1948), independently from
Adamantiades, described the disease for the second time. 3
I have three questions for the authors. First, I have found it
difficult to delineate normal from diseased artery segments when
selecting a site for anastomosis in these patients, and I wonder how
the authors advise doing this. Second, because pseudoaneurysms
occur at the anastomoses of both prosthetic and vein grafts in these
patients, I believe that endovascular reconstructionmay be safer, as
has been described by others.4-6 Would the authors comment on
the role of endovascular grafts in patients with Adamantiades-
Behçet disease? Third, when a bypass is needed for limb salvage
after arterial thrombosis, reinforcement of the anastomosis by
wrapping it with a synthetic (Dacron [DuPont, Wilmington, Del]
or polytetrafluoroethylene) band would offer a theoretical support
against the development of pseudoaneurysms. Would the authors
comment on this?
Athanasios D. Giannoukas, MSc, MD, PhD, EBSQVASC
Division of Vascular Surgery
University Hospital of Larissa
University of Thessaly Medical School
Larissa, Greece
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Despite such letters to the editor that typically appear after any
scientific article on Behçet’s disease, the medical literature widely
recognizes the appropriateness of eponym “Behçet.” A simple
search in Medline retrieves more than 5,000 references for Behçet
or Behçet’s disease, compared with only about 70 for Adamantia-
des-Behçet disease. Many of the latter are letters written in a quite
similar manner and concerned mainly with the eponym “Behçet”
rather than scientific contribution.
The fact is, it was Dr Hulusi Behçet who first recognized the
syndrome, correctly defined its characteristics, and described the
classic triad that is still a worldwide guide in today’s modern
medicine.1 He put special emphasis on the recurrent aphthous
stomatitis (ie, oral ulcerations) that is considered the universal
hallmark of the disease and a key to diagnosis. The International
Society for Behçet’s Disease acknowledges his contribution in the
official web site as follows:
Origins of the disease:
A Greek physician called Hippocrates, writing in 500 BC,
described a cluster of symptoms that seems to be that of Behçet’s
disease. However, although various researchers wrote about this
disorder after that time, it wasn’t until 1937 that it got its name. A
Turkish dermatologist called Hulusi Behçet published an article in
a German medical journal in which he said he had noticed a
characteristic set of symptoms in some of his patients which he
thought all belonged to a specific disorder. He listed the ‘classical’
set of symptoms of mouth and genital ulcers with eye inflammation
that identified it. Since then, other symptoms have been added to
the original list, but the name of Behçet has remained.2
After Hippocrates’ descriptions as an endemic disease in the
Middle East, very few observations of the unique symptoms ap-
peared in the medical literature until the early 1900s. In the
beginning, this complex was considered to be a manifestation of
syphilis, but in 1937, Behçet proposed a separate disease entity that
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by 1947 had gained widespread international recognition. Behçet
deserves to have the disease named after him, because he was the
first modern author to group the various ophthalmic, dermato-
logic, and oral-genital lesions together as a syndrome.3
On the other hand, Dr Adamantiades presented a case of a
young man with recurrent ocular lesions, and he observed that his
patient had many other manifestations as well. It is possible that
this young man was suffering from what we called Behçet’s disease
today. However, in his case report, Dr Adamantiades thought
three possible etiologies responsible for the clinical picture: syphi-
lis, tuberculosis, or staphylococcal infection. He didn’t recognize
the true nature of the disease and therefore was not able to describe
it as a syndrome. The patient received antisyphilitic treatment;
however, the disease was not cured. In addition, the presentation
of the case was from an ophthalmologist’s perspective for the most
part and naturally focused on the ocular lesions, as its title discloses.
Others reported similar observations long before Adamantiades.
His report contains nothing original in this regard.
As to answer the other questions, we consider endovascular
techniques a potential future option in the treatment of these
patients, as mentioned in our article.4 However, it is not possible to
visually define the extent of disease within arterial segments with
this approach. Since surgical excision is not possible here, the
diseased tissue is left in place. Furthermore, whether or not these
devices may trigger a superposing inflammatory response will
remain uncertain until more data become available. Suture line
reinforcement is strongly advisable in vasculo-Behçet cases. Inspec-
tion of major pathologic evidence in adventitia or transected aortic
wall may give some clues for delineating the diseased segments
intraoperatively, though this represents a continuing challenge.
Zafer H. Iscan, MD
Kerem M. Vural, MD
Murat Bayazit, MD
Department of Cardiovascular Surgery
Turkiye Yuksek Ihtisas Hospital
Ankara, Turkey
REFERENCES
1. Behçet H. Uber rezidivier apthose, durch ein Virus verurachte Geschwire
am Mund, am Auge und Genitalien. Dermatol Wochnschr 1937;105:
1152.
2. Behçet’s Syndrome Society. http://www.behcets-society.fsnet.co.uk/
re_soc.html. Accessed Apr 8, 2005.
3. Ehrlich GE. Behçet’s disease and thrombophilia. Ann Rheum Dis 2002;
61:381.
4. Iscan ZH, Vural KM, Bayazit M. The compelling nature of arterial
manifestations in Behçet’s disease. J Vasc Surg 2005; 41:53-8.
doi:10.1016/j.jvs.2005.03.039
Regarding “Extension of saphenous thrombus into
the femoral vein: a potential complication of new
endovenous ablation techniques”
Although the extension of saphenous thrombus into the fem-
oral vein is a potential complication of new endovenous ablation
techniques (J Vasc Surg 2005;41:130-5), it is very rare. Most
published data on endovenous laser ablation have supported per-
forming the technique in the absence of general or spinal anesthe-
sia.1,2 However, it is of great importance to perform the procedure
under adequate tumescent anesthesia, which allows the operator to
obtain feedback from the patient and avoid overtreatment of the
vein. Complete collapse of the vein also minimizes thrombotic
occlusion. Insertion of the catheter, whether radiofrequency or
laser, into the common femoral vein (CFV) must be avoided at all
costs to reduce damage to the CFV or the great saphenous vein
(GSV) proximal to the epigastric vein.
In our own experience at the Arizona Heart Institute with
1,000 cases, we have seen only one pulmonary embolus in a
patient with leg ulcer who weighed350 pounds. Her ultrasound
scan on the fifth day did not show any thrombus extending into the
CFV. She was not as ambulatory as most of our other patients, who
return to normal activity in 2 days.
The original instructions for radiofrequency ablation (VNUS
closure system, San Jose, Calif) called for placement of the catheter
in the CFV with pullback into the GSV. After Dr Hingorani’s
presentation at the American Venous Forum meeting in February
2004,3 we cautioned the company that this practice could lead to
intimal damage, especially in smaller veins.
Maintaining physiologic drainage at the saphenofemoral junc-
tion is the most important aspect in the endovenous closure
technique, which has been well illustrated in our observations and
by Pichot et al.4 We strongly believe that the procedure should be
done under complete tumescent anesthesia, without any intrave-
nous sedation. Furthermore, only minimal manipulation should be
done at the saphenofemoral junction.
Rajagopalan Ravi, MD, FACS
Julio Rodriguez-Lopez, MD, FACS
Venkatesh Ramaiah, MD, FACS
Edward B. Diethrich, MD, FACS
Arizona Heart Institute and Hospital
Phoenix, Ariz
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We greatly appreciate the comments of Dr Ravi and his
colleagues from the ArizonaHeart Institute. With an experience of
1,000 endovenous cases, it is commendable that they observed
only one pulmonary embolism. We wonder if all of their patients
(beyond their published early experience) had early postoperative
duplex scanning and what was the rate of extension of thrombus
from the saphenous vein toward the common femoral vein (CFV)?
The purpose of our communication was to stress that the
extension of saphenous thrombus into the femoral vein after
endovenous ablation may not be as rare as originally believed,
especially in early experience with this technique.
Their comment that avoiding insertion of the catheter,
whether radiofrequency or laser, into the CFV must be avoided to
reduce damage to the CFV or the great saphenous vein (GSV)
proximal to the epigastric vein makes sense, although no evidence
is given that it indeed makes a difference. Most manufacturers, as
well as Min et al,1 recommend advancing the catheter into the
common femoral vein and pulling it back to the saphenous vein. In
Min’s large experience, no deep venous thrombosis was reported
in 499 patients, despite commencing the ablation above the epi-
gastric vein (5 to 10 mm from the saphenofemoral junction). We
have always positioned the laser probe 10 mm distal to the epigas-
tric vein and have modified our technique to keep manipulation
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